Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;76(1):18-31.
doi: 10.1002/hep.32327. Epub 2022 Mar 22.

A revised electronic version of RUCAM for the diagnosis of DILI

Affiliations

A revised electronic version of RUCAM for the diagnosis of DILI

Paul H Hayashi et al. Hepatology. 2022 Jul.

Abstract

Background and aims: Roussel Uclaf Causality Assessment Method (RUCAM) for DILI has been hindered by subjectivity and poor reliability. We sought to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI Registry, published literature, and iterative computer modeling.

Approach and results: RUCAM criteria were updated, clarified, and computerized. We removed criteria 3 (risk factors) for lack of added value and criteria 4 because we felt it more useful to assess each drug separately. Criteria 6 (drug-specific risk) was anchored to LiverTox likelihood scores. Iterative testing in subsets of 50-100 single-agent, nonherbal cases from both registries was done to optimize performance. We used classification tree analysis to establish diagnostic cutoffs for this revised electronic causality assessment method (RECAM) and compared RECAM with RUCAM for correlation with expert opinion diagnostic categories in 194 DILI cases (98 DILIN, 96 Spanish DILI). Area under receiver operator curves for identifying at least probable DILI were the same at 0.89 for RECAM and RUCAM. However, RECAM diagnostic categories have better observed overall agreement with expert opinion (0.62 vs. 0.56 weighted kappa, p = 0.14), and had better sensitivity to detect extreme diagnostic categories (73 vs. 54 for highly likely or high probable, p = 0.02; 65 vs. 48 for unlikely/excluded, p = 0.08) than RUCAM diagnostic categories.

Conclusions: RECAM is an evidence-based update that is at least as capable as RUCAM in diagnosing DILI compared with expert opinion but is better than RUCAM at the diagnostic extremes. RECAM's increased objectivity and clarity will improve precision, reliability, and standardization of DILI diagnosis, but further refinement and validation in other cohorts are needed.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Box and whisker plots showing median, inter-quartile, outliers and Spearman’s rho values for (a) RECAM and (b) RUCAM scores by expert opinion diagnostic categories. 98 DILIN and 96 Spanish Registry cases combined (n = 194). Horizontal lines represent diagnostic score cut-offs for RECAM and RUCAM. Downward pointing arrowheads indicate that the cut-off integer value is included in the category below the line. DILIN categories of definite and highly likely were combined and considered equivalent to Spanish Registry high probable category (labeled High Probable/Highly Likely). Spanish Registry unlikely and excluded categories were combined and considered equivalent to DILIN unlikely category (labeled Unlikely/Excluded).
Figure 1:
Figure 1:
Box and whisker plots showing median, inter-quartile, outliers and Spearman’s rho values for (a) RECAM and (b) RUCAM scores by expert opinion diagnostic categories. 98 DILIN and 96 Spanish Registry cases combined (n = 194). Horizontal lines represent diagnostic score cut-offs for RECAM and RUCAM. Downward pointing arrowheads indicate that the cut-off integer value is included in the category below the line. DILIN categories of definite and highly likely were combined and considered equivalent to Spanish Registry high probable category (labeled High Probable/Highly Likely). Spanish Registry unlikely and excluded categories were combined and considered equivalent to DILIN unlikely category (labeled Unlikely/Excluded).

Comment in

References

    1. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–30. - PubMed
    1. Chalasani NP, Maddur H, Russo MW, et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol 2021;116:878–898. - PubMed
    1. European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guideline Panel C, Panel m, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 2019;70:1222–1261. - PubMed
    1. Kaplowitz N Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308–10. - PubMed
    1. Hayashi PH. Causality assessment in drug-induced liver injury. Semin Liver Dis 2009;29:348–56. - PubMed

Publication types